289 related articles for article (PubMed ID: 28154084)
1. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract][Full Text] [Related]
2. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
Gould C; Lickiss J; Kankanige Y; Yerneni S; Lade S; Gandhi MK; Chin C; Yannakou CK; Villa D; Slack GW; Markham JF; Tam CS; Nelson N; Seymour JF; Dickinson M; Neeson PJ; Westerman D; Blombery P
Br J Haematol; 2021 Oct; 195(1):113-118. PubMed ID: 34426978
[TBL] [Abstract][Full Text] [Related]
5. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
[TBL] [Abstract][Full Text] [Related]
6. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
[TBL] [Abstract][Full Text] [Related]
7. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
[TBL] [Abstract][Full Text] [Related]
8. Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.
Mohammadian Haftcheshmeh S; Zamani P; Mashreghi M; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Biotechnol Prog; 2021 Mar; 37(2):e3095. PubMed ID: 33118322
[TBL] [Abstract][Full Text] [Related]
9. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
Mariuzza RA; Shahid S; Karade SS
J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
[TBL] [Abstract][Full Text] [Related]
10. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE; Wolfers J; Martin-Garcia N; Gaulard P; Triebel F
Eur J Cancer; 2001 Sep; 37(13):1709-18. PubMed ID: 11527700
[TBL] [Abstract][Full Text] [Related]
11. Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.
Guéry JC; Sette A; Leighton J; Dragomir A; Adorini L
J Exp Med; 1992 May; 175(5):1345-52. PubMed ID: 1569402
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
13. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
14. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
[TBL] [Abstract][Full Text] [Related]
15. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men.
Holling TM; Schooten E; van Den Elsen PJ
Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183
[TBL] [Abstract][Full Text] [Related]
16. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
Bhagwat B; Cherwinski H; Sathe M; Seghezzi W; McClanahan TK; de Waal Malefyt R; Willingham A
J Immunol Methods; 2018 May; 456():7-14. PubMed ID: 29427592
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.
Liang B; Workman C; Lee J; Chew C; Dale BM; Colonna L; Flores M; Li N; Schweighoffer E; Greenberg S; Tybulewicz V; Vignali D; Clynes R
J Immunol; 2008 May; 180(9):5916-26. PubMed ID: 18424711
[TBL] [Abstract][Full Text] [Related]
18. Early human T cell activation events with engagement of surface MHC class II.
King RL; Nguyen QV
J Cell Biochem; 1998 Sep; 70(3):346-53. PubMed ID: 9706872
[TBL] [Abstract][Full Text] [Related]
19. Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.
Wu S; Yang Y; Sadegh-Nasseri S; Ashwell JD
J Immunol; 1993 Mar; 150(6):2211-21. PubMed ID: 8450208
[TBL] [Abstract][Full Text] [Related]
20. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
Wierz M; Pierson S; Guyonnet L; Viry E; Lequeux A; Oudin A; Niclou SP; Ollert M; Berchem G; Janji B; Guérin C; Paggetti J; Moussay E
Blood; 2018 Apr; 131(14):1617-1621. PubMed ID: 29439955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
